埃索美拉唑获批适应症

What are the approved indications? Many patients have asked this question recently. Let’s take a look at it together. Esomeprazole is used for the treatment of gastroesophageal reflux disease (GERD), including the treatment of erosive reflux esophagitis, long-term maintenance treatment to prevent recurrence of cured esophagitis patients, and symptom control of gastroesophageal reflux disease (GERD). Esomeprazole combined with appropriate antimicrobial therapy can eradicate Helicobacter pylori, heal duodenal ulcers associated with Helicobacter pylori infection, and prevent the recurrence of peptic ulcers associated with Helicobacter pylori infection.

Esomeprazole Medication Guide:

1. Treatment of erosive reflux esophagitis: 40 mg once a day for 4 weeks. For patients whose esophagitis is not cured or whose symptoms persist, a further 4 weeks of treatment is recommended.

2. Long-term maintenance treatment for cured esophagitis patients to prevent recurrence: 20 mg once a day.

3. Symptom control of GERD (gastroesophageal reflux disease): patients without esophagitis take 20 mg once a day. If symptoms are not controlled after 4 weeks of medication, the patient should undergo further examination. After the symptoms disappear, immediate therapy can be used (ie, 20 mg orally, once a day if necessary).

4. Combined antimicrobial therapy to eradicate Helicobacter pylori: Use a combined medication regimen of 20 mg of this drug once, 1 g of amoxicillin once, and 500 mg of clarithromycin once, twice a day for 7 days.

Tablets should be swallowed whole with liquid and should not be chewed or crushed.

For patients with difficulty swallowing, put it into boiled water until the tablet is completely disintegrated and take it within 30 minutes.

Esomeprazole is the S-isomer of omeprazole. It reduces gastric acid secretion through a specific targeting mechanism and is a specific inhibitor of proton pumps in parietal cells. In a clinical comparative study of esomeprazole and omeprazole in the treatment of reflux esophagitis, the total effective rate of esomeprazole was 97.18%, which was significantly higher than 84.51% of omeprazole, and there was no significant difference in the incidence of adverse reactions. Chen Caiming conducted a cost-effectiveness analysis of omeprazole and esomeprazole in the treatment of duodenal ulcer. The recovery rate of the esomeprazole group was 92.6%, which was higher than that of omeprazole, which was 78.6%. The results proved that it has cost and effectiveness advantages.